About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Generics
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Duties of Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Shyam S Bhartia
Hari S Bhartia
Sushil Kumar Roongta
Vivek Mehra
Arun Seth
Shirish G. Belapure
Shivpriya Nanda
Harsh Mahajan
Priyavrat Bhartia
Arjun Shanker Bhartia
Arvind Chokhany
Dr. Ramakrishnan Arul
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Generics
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Policy on Materiality of Related Party Transactions and Dealing with Related Party Transactions
Policy on Board Diversity
Policy for Determining Material Subsidiaries
Whistle Blower Policy
Corporate Social Responsibility Policy
Code of Conduct for Directors and Senior Management
Code for Independent Directors
Appointment and Remuneration Policy
Familiarisation Programme for Independent Directors
Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information
Policy for Determination of Materiality of Events and Information
Archival Policy
Dividend Distribution Policy
Silent Period Policy
Corporate Tax Policy
Grievance Redressal policy
Risk Management Policy
Duties of Directors
Independence Criteria for Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
What are you looking for?
×
Information Report etc
Home
Information Report etc
Information, Report etc
2021-22
Q1
NCD Transfer - Record Date Intimation - May 7, 2021
2020-21
Q1
Stock Exchange Disclosure - Approval of Issue of NCDs - May 29, 2020
Stock Exchange Disclosure - Issue of NCDs - June 2, 2020
Q3
Stock Exchange Disclosure - Issue of NCDs - November 4, 2020
Q4
Issue of Non-Convertible Debentures - January 14, 2021
2019-20
Q2
Notice for Payment of Interest on NCDs - July 29, 2019
Notice for Record date and Interest payment on NCDs - August 8, 2019
Notice for Record date and Interest payment on NCDs - July 2, 2019
Q3
Approval of Early Redemption of NCDs - December 30, 2019
Notice of Committee Meeting for Early Redemption of NCDs - December 11, 2019
Q4
Redemption of NCDs - January 08, 2020
2018-19
Q1
Proposal to Consider Issue of NCDs - Junne 22, 2018
Q2
Issue of NCDs - September 5, 2018
Notice for Record date and Interest Payment on NCDs - July 2, 2018
Payment of Interest on NCDs - July 27, 2018
Q3
Record Date for redemption and payment of Interest on NCDs - December 31, 2018
Q4
Half Yearly Interest Payment on NCDs - January 28, 2019
Interest Payment on NCDs - March 6, 2019
Notice of Record Date for Interest Payment on NCDs - February 6, 2019
Redemption and Final Interest Payment to NCD Holders - January 25, 2019
2017-18
Q1
Acquisition of Radiopharmacy business of Triad Isotopes - May 5, 2017
Record date for payment of interest on NCDs - June 30, 2017
Q2
Half Yearly Interest Payment on NCDs - July 10, 2017
Half Yearly Interest Payment on NCDs - July 28, 2017
Q3
Certificate of Debenture Trustee - October 28, 2017
Half Yearly Interest Payment on NCDs - December 29, 2017
Q4
Half Yearly Interest Payment on NCDs - January 29, 2018
2016-17
Q4
Issuance of NCDs - January 27, 2017